Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

MOTS-c peptide: does it work, is it legal, and what does it cost?

A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about MOTS-c
Does it work in people?Evidence: Animal-only evidence

No randomized human trial of this peptide; the grade rests on animal and lab studies. See the evidence

Is it legal?Regulatory: HHS interim policy (draft)

Not FDA approved. HHS's draft policy covers single-ingredient compounding under strict conditions. Blends are not covered. [9] [10] See legal status

What does it cost?No FDA approved product and no verified compounded price. Insurance does not cover it. See cost by channel
Side effects?No systematic human safety data published. Injection site reactions reported anecdotally. Theoretical risk of hypoglycemia given AMPK activation and improved glucose uptake in mice (not demonstrated in humans). See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is MOTS-c?

MOTS-c is a 16 amino acid peptide encoded by mitochondrial DNA (the separate genetic code inside the cell's energy-producing mitochondria) that acts as a metabolic signal. In mice it activates AMPK, the cell's energy sensor, prevents diet induced obesity and insulin resistance, and improves exercise capacity and physical decline with age, but human evidence is limited to circulating levels that rise with exercise and a genetic variant linked to diabetes risk, with no published human treatment trial. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient MOTS-c by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add MOTS-c to the bulks list, and does not change its evidence grade.

MOTS-c is a mitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA. It is also known as Mitochondrial open reading frame of the 12S rRNA type-c, MOTS c, Mitochondrial derived peptide MOTS-c, MOTS-c peptide, MOTSc, MOTS c peptide.

How does it work?

MOTS-c is translated from a short open reading frame inside the mitochondrial 12S rRNA gene. In cells and mice it inhibits the folate cycle and de novo purine synthesis, which raises AICAR and activates AMPK, increasing glucose uptake and fatty acid oxidation in skeletal muscle. Under metabolic stress it moves into the nucleus and regulates stress response genes. Circulating levels in people rise acutely with exercise and fall with age. All mechanistic work is in cells and rodents.

Key facts
ClusterLongevity and mitochondrial
RoutesSubcutaneous injection (as sold); Intraperitoneal injection (animal studies)
Conditions studiedObesity and chronic weight management; Type 2 diabetes; Longevity and healthy aging; Insulin resistance and prediabetes; Mitochondrial disease and dysfunction
Recordv3, reviewed, verified Nov 1, 2026

MOTS-c benefits: what the evidence shows

Evidence: Animal-only evidenceGrade assigned per the methodology.

The foundational 2015 mouse study showed that MOTS-c injection prevented high fat diet induced obesity and insulin resistance and improved glucose handling in aged mice. A 2021 study showed that circulating MOTS-c rises with exercise in young men and that treating mice, including old mice, improved running capacity and physical performance. Human data are observational: an East Asian mitochondrial DNA variant that changes the MOTS-c sequence is associated with type 2 diabetes in men. No human interventional trial of MOTS-c has been published, and a phase 1 study of a related analog by a former sponsor was never published in a peer reviewed journal. The human study is a genetic association study, not an intervention with the peptide; it is listed but does not raise the grade.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials0n/a
Human observational studies1n/a
Animal studies2n/a
All indexed studies3n/a

Human evidence

No indexed human treatment trial identified. Reynolds et al. 2021 measured MOTS-c in skeletal muscle and plasma of 10 healthy young men before and after exercise and found it rose acutely. Zempo et al. 2021 reported that the m.1382A>C mitochondrial DNA variant, which substitutes lysine 14 with glutamine in MOTS-c, was associated with type 2 diabetes in Japanese men and reduced the peptide's metabolic activity in cells. These are correlational findings, not treatment effects.

Animal evidence

Lee et al. 2015: daily intraperitoneal MOTS-c (0.5 mg/kg) prevented weight gain and insulin resistance in mice on a high fat diet and improved insulin sensitivity in aged mice, working through AMPK activation in skeletal muscle. Reynolds et al. 2021: MOTS-c treatment (15 mg/kg) improved treadmill running in young, middle aged, and old mice, and late life treatment improved physical capacity and some healthspan measures.

Key studies

Indexed studies of MOTS-c
StudyDesign and populationOutcomeGrade
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance2015 PMID 25738459Mouse studies with cell culture mechanism workMice on high fat diet and aged mice; cultured muscle cellsMOTS-c prevented diet induced obesity and insulin resistance and improved insulin sensitivity in aged mice through folate cycle inhibition and AMPK activationEvidence: Animal-only evidence
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis2021 PMID 33473109Human exercise sampling study plus mouse treatment studiesn = 10 10 healthy young men (sampling only) and young, middle aged, and old mice (treatment)MOTS-c rose in human muscle and plasma after exercise; treated mice of all ages improved running capacity and late life treatment improved physical performanceEvidence: Animal-only evidence
A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c2021 PMID 33468709Genetic association study with cell and mouse functional workJapanese adults with and without type 2 diabetesThe m.1382A>C variant (MOTS-c K14Q) was associated with type 2 diabetes in men and the variant peptide had reduced metabolic activityEvidence: Human observational evidence

Conditions studied

Conditions with evidence for MOTS-c
ConditionGradeNote
Obesity and chronic weight managementNot gradedGLP-1 based peptides are the only peptides with large randomized trials for weight loss. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks and tirzepatide 15 mg produced 20.9% over 72 weeks. Retatrutide, cagrilintide, and survodutide are in late stage trials.
Type 2 diabetesNot gradedSeveral peptide drugs are FDA approved for type 2 diabetes, including insulin, GLP-1 receptor agonists, tirzepatide, and pramlintide. GLP-1 agonists and tirzepatide lower HbA1c by about 1 to 2 percentage points and reduce weight; semaglutide also reduces cardiovascular events.
Longevity and healthy agingEvidence: Animal-only evidenceMitochondrial derived peptide that improved metabolic homeostasis in mice; the only human data are genetic association studies that do not raise the grade; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product.
Insulin resistance and prediabetesEvidence: Animal-only evidencePrevented diet induced insulin resistance in mice; human genetic association data do not raise the grade.
Mitochondrial disease and dysfunctionEvidence: Animal-only evidenceImproved metabolism and physical capacity in mice; human data measure natural levels after exercise only.

Is MOTS-c legal in the United States?

Regulatory: HHS interim policy (draft)WADA: WADA prohibited

FDA and compounding status

MOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

  2. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

  3. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

  4. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  5. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

  6. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for MOTS-c or the category-wide tracker.

Email me when MOTS-c's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of MOTS-c used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature. Mouse studies used 0.5 mg/kg per day intraperitoneally (metabolic studies) and up to 15 mg/kg (exercise studies). No human dose finding or pharmacokinetic study has been published.

Routes reported

Routes of administration reported for MOTS-c
#Route
1Subcutaneous injection (as sold)
2Intraperitoneal injection (animal studies)

MOTS-c side effects

Side effects

Side effects reported for MOTS-c
#Reported side effect
1No systematic human safety data published
2Injection site reactions reported anecdotally
3Theoretical risk of hypoglycemia given AMPK activation and improved glucose uptake in mice (not demonstrated in humans)

Interactions

Interactions reported for MOTS-c
#Interaction
1No formal human interaction studies exist
2Theoretical additive glucose lowering with insulin, sulfonylureas, metformin, or GLP-1 agonists, based on mouse AMPK data (not tested)

Contraindications

Contraindications for MOTS-c
#Contraindication
1Pregnancy and breastfeeding (no data)
2History of hypoglycemia or insulin treated diabetes without medical supervision (theoretical)
3Competitive athletes subject to WADA testing (prohibited at all times under S4.4)

How do people access MOTS-c legally?

Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.

Access options

  • Conditional

    Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient MOTS-c by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.

  • Not available

    Not available as an FDA approved product.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare MOTS-c

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [11] [12] [13]

In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c as a single-ingredient product by subcutaneous or intramuscular injection, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put MOTS-c on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix MOTS-c with other peptides are not covered, and state rules still apply. [9] [10]

What FDA found

  • July 2026: FDA's review found a holistic clinic that says it gets compounded MOTS-c from compounding pharmacies, and a wellness clinic selling an IV therapy that contains MOTS-c. [14]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [11] [15] [16] [17] [18] [19]

What that means for you

  • A pharmacy that compounds MOTS-c relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [10]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [17]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, MOTS-c is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [6]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [19]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [24] [25]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [13] [25] [26]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [19] [27] [28] [29] [30] [31]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [13]
  • Pharmacy: Is this made for me on a prescription written in my name? [26]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [13] [25]
  • Prescriber: What is the legal basis for a pharmacy to compound MOTS-c? Is it FDA approved or on the 503A bulks list? [4] [19]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [13]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [20]

Frequently asked questions

What is MOTS-c peptide?

MOTS-c is a 16 amino acid peptide encoded by mitochondrial DNA, the separate genes inside the cell's energy-producing mitochondria, rather than the cell nucleus. It acts as a metabolic signal: in mice it activates AMPK, the cell's energy sensor, improves insulin sensitivity (how well the body responds to insulin), and rises with exercise. It is marketed for weight loss, energy, and healthy aging, but no human treatment trial has been published. It is not FDA approved. In July 2026 FDA's drug center recommended against adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients) and the advisory committee voted in favor, and in October 2026 HHS released a draft policy under which it does not intend to take enforcement action against licensed pharmacies that compound single-ingredient MOTS-c under strict conditions. [1] [2] [5] [10]

Is MOTS-c legal in the United States?

It is not an FDA approved drug, but possessing it is not a crime. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient MOTS-c by injection under the skin or into muscle on a patient-specific prescription, under strict quality and reporting conditions. It is a draft, not an approval or a bulks listing, and HHS may revisit it. Blends and stacks are not covered, and state law still applies. Research chemical products sold for human use are still unapproved drugs. [4] [5] [8] [9] [10]

MOTS-c benefits: what does the evidence show?

The benefit claims come from mice. MOTS-c injections prevented diet induced obesity and insulin resistance, improved glucose handling in older mice, and improved running capacity and physical function in young, middle aged, and old mice. In people, the evidence is only that blood and muscle levels rise with exercise and that a genetic variant in the MOTS-c sequence is linked to diabetes risk. PeptideAgent grades the evidence animal-only. [1] [2] [3]

Does MOTS-c work for weight loss or insulin resistance?

In mice, yes: daily injections prevented diet induced obesity and insulin resistance and improved glucose handling in old mice. In humans, nobody knows, because no treatment trial has been published. The human evidence is that blood levels rise with exercise and that a genetic variant in the MOTS-c sequence is linked to diabetes risk in Japanese men. PeptideAgent grades the evidence animal-only. [1] [2] [3]

Is MOTS-c an exercise mimetic?

That is the claim from mouse data. In the 2021 Nature Communications study, MOTS-c rose in muscle and plasma of young men after exercise, and injecting it improved treadmill performance in young, middle aged, and old mice. Whether injecting it improves fitness or physical function in people has not been tested. [2]

What are the side effects of MOTS-c?

There is no systematic human safety data. Anecdotal reports mention injection site irritation. Because it activates AMPK and increases glucose uptake in mice, low blood sugar is a theoretical concern, especially alongside diabetes medications, but this has not been studied in people. [1]

How is MOTS-c taken?

Mouse studies gave it by injection into the abdominal cavity. Products sold to people are subcutaneous injection vials. No human dose finding study exists, so any human regimen is extrapolated from rodent work rather than measured. PeptideAgent does not give doses for unapproved peptides. [1] [2]

How much does MOTS-c cost?

There is no verified price. HHS's October 2026 draft policy says HHS does not intend to take enforcement action against licensed pharmacies that compound single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified compounded price, and advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. [8] [10]

Is MOTS-c banned by WADA?

Yes. MOTS-c is named on the WADA Prohibited List under section S4.4 (metabolic modulators) as an activator of AMP-activated protein kinase, and it is prohibited at all times, in and out of competition. [6] [7]

MOTS-c vs humanin: what is the difference?

Both are mitochondrial derived peptides encoded in the mitochondrial genome. MOTS-c (16 amino acids, from the 12S rRNA region) acts mainly on metabolism through AMPK. Humanin (24 amino acids, from the 16S rRNA region) was discovered as a neuroprotective factor and acts on cell survival and insulin signaling. Both have mouse data and human blood level associations only; neither has a published human treatment trial. FDA's own 2026 briefing recommended against adding MOTS-c to the compounding bulks list; humanin has no FDA review history. [1] [2]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
  2. [2]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
  3. [3]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
  4. [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  5. [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  6. [6]WADA Prohibited List, section S4.4 metabolic modulatorsWADA, 2026
  7. [7]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
  8. [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  9. [9]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
  10. [10]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history)2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, November 1). MOTS-c: evidence, legality, and access. https://peptideagent.ai/peptides/mots-c
HTML link
<a href="https://peptideagent.ai/peptides/mots-c">MOTS-c: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.